摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-((3-phenylpropyl)amino)pyrazolo[1,5-a]pyrimidin-6-yl)acetic acid | 1454611-45-0

中文名称
——
中文别名
——
英文名称
(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-((3-phenylpropyl)amino)pyrazolo[1,5-a]pyrimidin-6-yl)acetic acid
英文别名
(2S)-2-tert-butoxy-2-[7-(8-fluoro-5-methyl-chroman-6-yl)-5-methyl-2-(3-phenylpropylamino)pyrazolo[1,5-a]pyrimidin-6-yl]acetic acid;(2S)-2-[7-(8-fluoro-5-methyl-3,4-dihydro-2H-chromen-6-yl)-5-methyl-2-(3-phenylpropylamino)pyrazolo[1,5-a]pyrimidin-6-yl]-2-[(2-methylpropan-2-yl)oxy]acetic acid
(2S)-2-(tert-butoxy)-2-(7-(8-fluoro-5-methylchroman-6-yl)-5-methyl-2-((3-phenylpropyl)amino)pyrazolo[1,5-a]pyrimidin-6-yl)acetic acid化学式
CAS
1454611-45-0
化学式
C32H37FN4O4
mdl
——
分子量
560.669
InChiKey
HAAIYOBMDJKOLO-PMERELPUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.3
  • 重原子数:
    41
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.41
  • 拓扑面积:
    98
  • 氢给体数:
    2
  • 氢受体数:
    8

文献信息

  • [EN] SULFAMIDE SODIUM CHANNEL INHIBITORS<br/>[FR] INHIBITEURS SULFAMIDES DES CANAUX DE SODIUM
    申请人:AMGEN INC
    公开号:WO2013134518A1
    公开(公告)日:2013-09-12
    The present invention provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that are inhibitors of voltage-gated sodium channels, in particular Nav 1.7. The compounds are useful for the treatment of diseases treatable by inhibition of sodium channels such as pain disorders. Also provided are pharmaceutical compositions containing compounds of the present invention.
    本发明提供了式I的化合物或其药学上可接受的盐,这些化合物是电压门控通道的抑制剂,特别是Nav 1.7。这些化合物对于治疗通过抑制通道可治疗的疾病,如疼痛障碍,是有用的。还提供了含有本发明化合物的药物组合物。
  • Inhibitors of Human Immunodeficiency Virus Replication
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US20130237499A1
    公开(公告)日:2013-09-12
    The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    该披露通常涉及到公式I的化合物,包括用于治疗人类免疫缺陷病毒(HIV)感染的组合物和方法。该披露提供了HIV的新型抑制剂,包含这些化合物的药物组合物,以及使用这些化合物治疗HIV感染的方法。
  • INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION
    申请人:Bristol-Myers Squibb Company
    公开号:EP2822950A1
    公开(公告)日:2015-01-14
  • US9006235B2
    申请人:——
    公开号:US9006235B2
    公开(公告)日:2015-04-14
  • [EN] INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION<br/>[FR] INHIBITEURS DE LA RÉPLICATION DU VIRUS DE L'IMMUNODÉFICIENCE HUMAINE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2013134142A1
    公开(公告)日:2013-09-12
    The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. (i)
查看更多